By Amara Osei

Wendy’s Company (NASDAQ: WEN) rejected Trian Fund Management’s $1.4 billion acquisition proposal and approved a shareholder rights plan, commonly called a “poison pill” (an anti-takeover mechanism), with a 15% ownership threshold through November 3, 2027. The board continues to reject the $7.35-per-share offer, while any investor exceeding 15% without board approval can face dilution of that stake.

What did the board reject?

Wendy’s board said the $7.35-per-share offer “undervalues the recovery potential and future earnings” of the fast-food chain. Trian, the activist fund led by Nelson Peltz, submitted the bid with Flynn Group, BlueFive Capital and Sixth Street Partners; an independent committee unanimously rejected it. ActivTrades analyst Ion Jauregui described the response as a “poison pill” intended to make a potential takeover more difficult. The board expects greater long-term value from remaining independent than from Trian’s proposal.

How does the threshold constrain control?

The rights plan permits Wendy’s to dilute the stake of any investor exceeding 15% without board approval, and it remains effective until November 3, 2027. The buyer group’s 16.3% holding already exceeds that threshold.

Can the independent turnaround reverse the sales decline?

Seven consecutive quarters of declining comparable sales (same-store sales) have placed the chain under pressure during a transformation under CEO Bob Wright. His strategy seeks to restore the brand’s appeal through three actions:

• Improve the company’s food offering.
• Increase marketing investment in the brand.
• Optimise the company’s restaurant operations.

Jauregui identified operational weakness as a central argument behind concerns about Wendy’s valuation. The board nevertheless believes the business can generate more long-term value independently than through Trian’s rejected offer.

Nelson Peltz explored a potential acquisition of Wendy’s in 2022, although that initiative did not move forward. His renewed buyer-group bid now opens the door to further negotiations or a confrontation with the board.

What is the market pricing?

Wendy’s shares traded around $8.15, approximately 11% above Trian’s $7.35 offer, when ActivTrades published its analysis. That premium suggests the market does not view the transaction as closed and may expect an improved offer or a competing bid for control.

Shares fell as low as $5.94 in October before rebounding by more than 30%, according to Jauregui. He attributed the recovery to corporate-transaction expectations and the recovery of technical levels. The market has begun to price an acquisition above the rejected proposal, while the rebound still reflects expectations rather than demonstrated fundamental improvement.

How fragile is the technical recovery?

Between 2020 and 2024, Wendy’s traded within a broad sideways range of $18.50 to $25.00. The break below that support at the end of 2024 triggered a bearish trend and a decline of more than 70%.

The October low and recovery through the $6.07-$6.82 support zone (a prior buying area) suggest selling pressure may be exhausting, although the long-term structure remains fragile. Shares regained long-term moving averages at $7.06 and $7.69. The daily RSI (Relative Strength Index) stands near 74, in overbought territory, while the MACD (moving average convergence and divergence) remains positive with a rising histogram.

What price levels matter next?

• Resistance levels (prior selling areas) at $8.50 and $9.00-$9.42 could open a path toward $10.00 if broken.
• Support levels (prior buying areas) stand at $7.69 and $7.35, followed by $7.06 and $6.82; $7.35 matches the rejected offer.

As long as Wendy’s trades above $7.35, the market is likely to sustain expectations of a possible improved offer. A correction toward that price would not necessarily undermine the bullish scenario, but a break below both $7.06 and $6.82 could signal that takeover expectations are losing momentum.

What can Trian do next?

Trian retains three strategic routes:

• Submit a higher offer for Wendy’s shares.
• Launch a proxy fight (a campaign to change the board).
• Accept Wendy’s independent transformation plan.

The central test is whether Wendy’s can restore growth and margins through Bob Wright’s independent strategy or whether shareholder pressure eventually forces a corporate transaction at a higher price. Any progress or breakdown in negotiations could trigger sharp movements in the share price.

What caveats accompany the analysis?

ActivTrades said the analysis does not constitute investment research, was not prepared under legal requirements designed to promote independence and should be treated as marketing communication. The material contains no record of ActivTrades prices or an offer or solicitation to transact in a financial instrument. The firm gives no warranty for accuracy or completeness.

ActivTrades does not consider recipients’ investment objectives or financial circumstances and describes itself as an execution-only service. It places responsibility for decisions on recipients and warns that past performance and forecasts do not reliably indicate future results. It also says political risk is unpredictable, central-bank actions can vary and platform tools cannot guarantee success.